No Data
Roth MKM Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $10
Roth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)
Buy Rating for Cardiol Therapeutics Driven by CardiolRx Progress and MAVERIC Phase 3 Trial Initiation
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
